Search Results - "Shergill, A"

LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET) by Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., Meyerhardt, J.A.

Get full text

Assessment of the impact of FcγRIIIA single-nucleotide polymorphisms on the efficacy of IgG1 monoclonal antibodies in patients with advanced gastroesophageal adenocarcinoma by A.V. Serritella, N.K.S. Grewal, B. Peterson, K. Arndt, D.D. Gaudio, P. Liu, A. Shergill, B. Polite, H.L. Kindler, D.V.T. Catenacci, C.Y. Liao

“…Background: Immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), such as trastuzumab and ramucirumab, are utilized in advanced gastroesophageal…”
Get full text

Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett's esophagus by Lee, J K, Cameron, R G, Binmoeller, K F, Shah, J N, Shergill, A, Garcia-Kennedy, R, Bhat, Y M

“…Barrett's esophagus with dysplasia is commonly treated with radiofrequency ablation (RFA). Despite its effectiveness, a concern of any ablative technique is…”
Get more information

MSR65 The Benefits of a Complex Identification and Stratification Model for Depression: Insights from a Large Claims Analysis Study by Popkov, A, Barrett, TS, Hohl, J, Shergill, A, Deakin, SL, Perry, M

Get full text

Alliance A022101/NRG-GI009: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer - Evaluating Radiation, Ablation and Surgery (ERASur) by Romesser, P.B., Miller, E.D., Shi, Q., Dixon, J.G., Gholami, S., White, S., Wu, C., Goulet, C.C., Jee, K.W., Wright, C., Yaeger, R., Shergill, A., Hong, T.S., George, T.J., O’Reilly, E., Meyerhardt, J., Hitchcock, K.E.

“…For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with…”
Get full text

Radiation Quality Control in the PROSPECT Trial by Mamon, H.J., Shi, Q., Smith, K.S., Colgrove, B., Quigley, J., Nelson, G., Weiser, M., Gollub, M.J., Saltz, L., Basch, E., Dueck, A., Goodman, K.A., George, T.J., Chang, G., Farma, J.M., Shergill, A., Fitzgerald, T., O’Reilly, E., Meyerhardt, J., Schrag, D.

“…PROSPECT (Clinical Trials.gov NCT01515787) is a prospective randomized trial of neoadjuvant chemoradiation vs. neoadjuvant FOLFOX with selective use of…”
Get full text

Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer – Evaluating Radiation, Ablation and Surgery (ERASur) by Romesser, P.B., Miller, E.D., Shi, Q., Dixon, J.G., Gholami, S., White, S., Wu, C., Goulet, C.C., Jee, K.W., Wright, C.L., Yaeger, R., Shergill, A., Hong, T.S., George, T.J., O'Reilly, E., Meyerhardt, J., Hitchcock, K.E.

“…For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with…”
Get full text

597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance) by Weiser, M., Shi, Q., Chang, G.J., Hakki, L., Goldberg, J., Auer, R., Gollub, M., Saltz, L., Musher, B.L., Al baghdadi, T., Farma, J., George, T., Colgrove, B., Nelson, G., O'Reilly, E.M., Shergill, A., Meyerhardt, J., Mamon, H., Schrag, D.

Get full text

LBA-5 Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study by Kawazoe, A., Xu, R., Passhak, M., Teng, H., Shergill, A., Gumus, M., Qvortrup, C., Stintzing, S., Towns, K., Kim, T., Shiu, K., Cundom, J., Ananda, S., Lebedinets, A., Fu, R., Jain, R., Adelberg, D., Heinemann, V., Yoshino, T., Élez, E.

Get full text

736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS) by Kyi, C.K., Spira, A., Carbone, D.P., Johnson, M.L., Henick, B.S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J.R., Catenacci, D., Liao, C-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A.R., Goldman, J.W.

Get full text

Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial by Hong, D., Shergill, A., Bazhenova, L., Cho, B.C., Heist, R., Moreno, V., Falchook, G.S., Nagasaka, M., Cassier, P., Besse, B., Kim, D.W., Yoon, S., Le, X., Zhao, T., Atwal, S., Park, E., Lee, J.

Get full text

Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy by YUKL, Steven A, SHERGILL, Amandeep K, WONG, Joseph K, HAVLIR, Diane V, MCQUAID, Kenneth, GIANELLA, Sara, LAMPIRIS, Harry, HARE, C. Bradley, PANDORI, Mark, SINCLAIR, Elizabeth, GIINTHARD, Huldrych F, FISCHER, Marek

“…To determine whether raltegravir-containing antiretroviral therapy (ART) intensification reduces HIV levels in the gut. Open-label study in HIV-positive adults…”
Get full text

A92 EDUCATIONAL INTERVENTIONS TO IMPROVE ERGONOMIC PERFORMANCE IN GASTROINTESTINAL ENDOSCOPY: A SYSTEMATIC REVIEW by Bansal, R, Scaffidi, M, Gimpaya, N, Fecso, A, Khan, R, Li, J, Torabi, N, Shergill, A, Grover, S

“…Abstract Background Physicians in procedural specialties, such as gastrointestinal endoscopy, are at a high risk of musculoskeletal injuries (MSPI) which can…”
Get full text

Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection by HSUE, Priscilla Y, GIRI, Kamini, ERICKSON, Sara, MACGREGOR, John S, YOUNES, Naji, SHERGILL, Amandeep, WATERS, David D

“…Patients with HIV infection exhibit increased rates of coronary events; however, the clinical features of acute coronary syndromes (ACS) in HIV-infected…”
Get full text

Outcome Disparities in Caucasian and non-Caucasian Patients with Myeloproliferative Neoplasms by Khan, I, Saraf, S.L, Shergill, A, Chen, Y.F, Patel, P.R, Quigley, J.G, Peace, D, Gordeuk, V.R, Hoffman, R, Rondelli, D

“…Abstract Background The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombotic and…”
Get full text

CD4+ T cell reconstitution, T cell activation, and memory T cell subset composition in blood and gut of HIV‐negative and ART‐suppressed HIV‐positive patients: implications for HIV persistence in the gut by Yukl, S, Sinclair, E, Epling, L, Li, Q, Shergill, A, McQuaid, K, Duan, L, Hare, B, Lampiris, H, Haase, A, Havlir, D, Wong, J

“…16‐17 July 2010, International AIDS Society’s Workshop “Towards a Cure”: HIV Reservoirs and Strategies to Control Them, Vienna, Austria…”
Get full text

Guidelines for endoscopy in pregnant and lactating women by Shergill, Amandeep K., MD, Ben-Menachem, Tamir, MD, Chandrasekhara, Vinay, MD, Chathadi, Krishnavel, MD, Decker, G. Anton, MD, Evans, John A., MD, Early, Dana S., MD, Fanelli, Robert D., MD, SAGES Representative, Fisher, Deborah A., MD, Foley, Kimberly Q., RN, SGNA Representative, Fukami, Norio, MD, Hwang, Joo Ha, MD, Jain, Rajeev, MD, Jue, Terry L., MD, Khan, Khalid M., MD, NASPHAGAN Representative, Lightdale, Jennifer, MD, Pasha, Shabana F., MD, Sharaf, Ravi N., MD, MS, Dominitz, Jason A., MD, MHS, Cash, Brooks D., MD

Get full text

Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C‐Infected Patients Undergoing Liver Transplantation by Shergill, Amandeep K., Khalili, Mandana, Straley, Stephanie, Bollinger, Kathy, Roberts, John P., Ascher, Nancy A., Terrault, Norah A.

“…Preliminary studies suggest preemptive anti‐HCV therapy in liver transplant recipients may enhance the rates of viral clearance, but the applicability and…”
Get full text

Percutaneous gastrostomy tubes in children with Pierre Robin sequence: efficacy, maintenance and complications by Al-Attar, Hyder, Shergill, Arvind K., Brown, Nicole E., Guernsey, Cindy, Fisher, David, Temple, Michael, John, Philip, Amaral, Joao G., Parra, Dimitri, Connolly, Bairbre L.

“…Background Children with Pierre Robin sequence (PRS) have significant oropharyngeal abnormalities, with respiratory and feeding difficulties. Gastrostomy tubes…”
Get full text

Prevalence of First-Step Mutants among Levofloxacin-Susceptible Invasive Isolates of Streptococcus pneumoniae in the United States by PLETZ, Mathias W. R, SHERGILL, Ardaman P, MCGEE, Lesley, BEAU, Bernard, WHITNEY, Cynthia G, KLUGMAN, Keith P

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text